<DOC>
	<DOCNO>NCT00139841</DOCNO>
	<brief_summary>SUMMARY : This multi-center open label study evaluate safety effectiveness Treanda™ ( also know bendamustine HCl SDX-105 ) patient indolent Non-Hodgkin 's lymphoma relapse within define timeframe take rituximab ( Rituxan® ) . Treanda give via 60-minute intravenous infusion day 1 2 every 21-day treatment cycle . Patients treat 6 cycle unless develop progressive disease unacceptable toxicity . Those continue receive clinical benefit end 6 cycle may receive additional 2 cycle . Following end treatment , patient follow 2 year disease progression start another anti-cancer therapy .</brief_summary>
	<brief_title>Safety Efficacy Treanda™ ( Bendamustine HCl ) Patients With Indolent Non-Hodgkin 's Lymphoma ( NHL ) Who Are Refractory Rituximab</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>ELIGIBILITY : Key Inclusion Criteria Documented Bcell NonHodgkin 's Lymphoma Small lymphocytic lymphoma ( ALC &lt; 5,000 cells/mm3 ) Marginal zone Bcell lymphoma ( nodal , extranodal , splenic type ) Lymphoplasmacytic lymphoma Follicular center lymphoma , follicular Disease document refractory fullcourse recent rituximab therapy ( single agent combination ) At least 1 prior chemotherapy regimen maximum 3 prior chemotherapy regimen Bidimensionally measurable disease ( CT scan ) least one lesion measure ≥ 2.0 cm single dimension Key Exclusion Criteria Patients receive rituximab part treatment ibritumomab tiuxetan ( Zevalin® ) eligible History prior high dose chemotherapy allogeneic stem cell support ( history autologous stem cell support permissible )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Lymphoma , Non-Hodgkin</keyword>
	<keyword>Rituximab Refractory</keyword>
	<keyword>Rituximab Failure</keyword>
	<keyword>Indolent Non-Hodgkins Lymphoma</keyword>
</DOC>